If Collaboration Fuels Biopharma Innovation, Why Can't We Connect More?

Biopharma’s most transformative advances—mRNA vaccines, CAR T therapies, and countless others—were made possible when organizations chose to break down silos and build on each other’s strengths. Collaboration accelerates discovery, expands access to expertise, and fuels innovation that no single group could achieve alone. Yet across the industry, teams still default to working in isolation. Why? Even with the desire to partner, structural constraints, entrenched habits, and financial pressures often create the perception that collaboration is risky or inefficient. Recent findings from the Global Biopharma Index highlight how these barriers continue to stall progress at a time when scientific challenges demand collective problem‑solving.

To better understand the disconnect—and how to move past it—Cytiva leaders share their perspectives on what makes collaboration difficult today and what it will take to build a culture where teamwork becomes the norm rather than the exception.